Product Code: 01-CARD-26
From £449.00 Early Bird
Early Bird Deadline: 31/10/2025
Deadline to order: 30/11/2025
Panel testing for Cardiac disorders (targeted NGS/ virtual panel /clinical exome / WES / WGS). This EQA has options for Arrythmia panel, Hypertrophic Cardiomyopathy panel, and all Cardiac Disorders.
Gene panel testing of genes associated with non-syndromic and syndromic forms of hypertrophic cardiomyopathy. The scope of this EQA is broadly in line with the genes designated high evidence (green) on the Genomics England Hypertrophic Cardiomyopathy Panel App.
CNV, MLPA, NGS, Panel testing, PCR based, Sanger sequencing, Whole exome sequencing, Whole genome sequencing
English, French, German, Italian, Spanish
DNA (in TE Buffer)
Yes
January 2026
January - March 2026
August 2026
You can complete purchase on our secure partner site.
The scheme is designed to assess the entire diagnostic pipeline of a laboratory, including sample receipt and processing, analytical processing (genotyping), and reporting (biological and clinical interpretation of the test result) in the context of a clinical referral, as well as reporting clarity, content and clerical accuracy.
Three mock clinical cases; two with matching samples and one virtual case will be provided.
Approximately 2µg DNA per sample is provided. Complete information will be available in scheme instructions.
Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.
Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.
Testing can be performed using any appropriate panel for genes associated with hypertrophic cardiomyopathy. To account for differing panel compositions, variants outside the stated scope of an individual laboratory’s panel will be excluded from their assessment. Only variants that have been validated in the test samples will be assessed.
Participants are expected to test samples according to their routine strategy, to return a clinical report and to complete the data collection form.
No restrictions on number of participants. Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc).
added wishlist!
View Wishlist
View Wishlist
Express your interest in ''.
